Elly Gerald Stoica

Array ( [id] => 15209773 [patent_doc_number] => 20190367573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => p53-BH3 Hybrids for Cancer Gene Therapy [patent_app_type] => utility [patent_app_number] => 16/414683 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14808355 [patent_doc_number] => 20190270787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/408748 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26111 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16408748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254197 [patent_doc_number] => 20190375832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => GARP-TGF-BETA 1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/409679 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26901 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117227 [patent_doc_number] => 20190345246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => Compositions and Methods for Treating Autoimmune Inner Ear Disease [patent_app_type] => utility [patent_app_number] => 16/407868 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241937 [patent_doc_number] => 20210361680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => INOSITOL-BASED IMMUNOTHERAPIES [patent_app_type] => utility [patent_app_number] => 17/051668 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695500 [patent_doc_number] => 10946069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer [patent_app_type] => utility [patent_app_number] => 16/401931 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 157 [patent_no_of_words] => 41827 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16401931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712835 [patent_doc_number] => 20190247481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => AVATAR DENDRITIC CELLS: THE NEOANTIGEN NATURAL KILLER T-CELL CHEMO IMMUNO RADIATION COMPOSITION INDUCING IMMUNOGENIC CELL DEATH [patent_app_type] => utility [patent_app_number] => 16/396220 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16396220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19104622 [patent_doc_number] => 11957695 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Methods and compositions targeting glucocorticoid signaling for modulating immune responses [patent_app_type] => utility [patent_app_number] => 16/396461 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 62 [patent_no_of_words] => 85863 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16396461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627265 [patent_doc_number] => 20220162280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => INTERLEUKIN 12 FUSION PROTEINS, AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 17/049021 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17049021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627265 [patent_doc_number] => 20220162280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => INTERLEUKIN 12 FUSION PROTEINS, AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 17/049021 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17049021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206315 [patent_doc_number] => 20190365844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ACTIVIN TYPE 2 RECEPTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/390394 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16390394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929957 [patent_doc_number] => 20190300616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => IL13Ralpha2 Binding Agents and Use Thereof in Cancer Treatment [patent_app_type] => utility [patent_app_number] => 16/385853 [patent_app_country] => US [patent_app_date] => 2019-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16385853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715693 [patent_doc_number] => 20190248910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => Methods of Inhibiting Activity Using Anti-CD27 Antibodies [patent_app_type] => utility [patent_app_number] => 16/382645 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16213907 [patent_doc_number] => 10729699 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists after anticancer therapy [patent_app_type] => utility [patent_app_number] => 16/374157 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15572 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414548 [patent_doc_number] => 10822424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Method of screening for anti-GARP antibodies [patent_app_type] => utility [patent_app_number] => 16/370822 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 44 [patent_no_of_words] => 39167 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16428303 [patent_doc_number] => 10828364 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-10 [patent_title] => Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions [patent_app_type] => utility [patent_app_number] => 16/367546 [patent_app_country] => US [patent_app_date] => 2019-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11616 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16367546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534605 [patent_doc_number] => 20190202924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1 RAP) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/358459 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -95 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16326864 [patent_doc_number] => 20200297829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => Integrative Immunotherapy for Cancer Treatment [patent_app_type] => utility [patent_app_number] => 16/356892 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14806339 [patent_doc_number] => 20190269779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => Liquid Formulation of Long-Lasting Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment [patent_app_type] => utility [patent_app_number] => 16/356319 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457699 [patent_doc_number] => 12098179 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes [patent_app_type] => utility [patent_app_number] => 16/981474 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23640 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981474 [rel_patent_id] =>[rel_patent_doc_number] =>)